CohBar, Inc. — Cyborg Score 2/10

Strategic Profile

CohBar held a differentiated position as the first company to mine the mitochondrial genome for therapeutically relevant peptides, establishing a robust IP portfolio. The company's lead candidate, CB4211, was in Phase 1b clinical trials for NASH and obesity. The merger with Morphogenesis shifted focus from mitochondrial therapeutics to personalized cancer vaccines and tumor microenvironment modulators under the new TuHURA Biosciences entity.

Cyborg Score Rationale

CohBar is no longer an independent operating company following its merger into TuHURA Biosciences (October 2023). The company's early-stage pipeline, limited clinical progress, and structural changes significantly limit its current relevance as a standalone entity.

Top Insights

• First-to-market advantage in mitochondrial genome exploitation for therapeutics with robust IP portfolio
• Merger completed in (October 2023) with Morphogenesis, creating TuHURA Biosciences focused on cancer immunotherapies
• Company no longer operating independently as of 2023
• Lead asset CB4211 for NASH/obesity discontinued post-merger

Named Competitors

• Exelixis — Oncology therapeutics
• Selecta Biosciences — Cell and gene therapy
• Forty Seven Inc — Immuno-oncology

Recent Developments

• (October 2023) Completed merger with Morphogenesis to form TuHURA Biosciences
• (May 2023) Announced definitive merger agreement with Morphogenesis
• (October 2021) Raised $15 million in public offering

Open the full interactive CohBar, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.